<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>23(1)</volume><submitter>Brendel C</submitter><pubmed_abstract>Gene therapy for hematological disorders relies on the genetic modification of CD34(+) cells, a heterogeneous cell population containing about 0.01% long-term repopulating cells. Here, we show that the lentiviral vector CD133-LV, which uses a surface marker on human primitive hematopoietic stem cells (HSCs) as entry receptor, transfers genes preferentially into cells with high engraftment capability. Transduction of unstimulated CD34(+) cells with CD133-LV resulted in gene marking of cells with competitive proliferative advantage in vitro and in immunodeficient mice. The CD133-LV-transduced population contained significantly more cells with repopulating capacity than cells transduced with vesicular stomatitis virus (VSV)-LV, a lentiviral vector pseudotyped with the vesicular stomatitis vir</pubmed_abstract><journal>Molecular therapy : the journal of the American Society of Gene Therapy</journal><pagination>63-70</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4426797</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>CD133-targeted gene transfer into long-term repopulating hematopoietic stem cells.</pubmed_title><pmcid>PMC4426797</pmcid><pubmed_authors>Kneissl S</pubmed_authors><pubmed_authors>Abel T</pubmed_authors><pubmed_authors>Schwable J</pubmed_authors><pubmed_authors>Buchholz CJ</pubmed_authors><pubmed_authors>Serve H</pubmed_authors><pubmed_authors>Muller-Kuller U</pubmed_authors><pubmed_authors>Bystrykh L</pubmed_authors><pubmed_authors>Kunkel H</pubmed_authors><pubmed_authors>Brendel C</pubmed_authors><pubmed_authors>Brugman M</pubmed_authors><pubmed_authors>Grez M</pubmed_authors><pubmed_authors>Daniela A</pubmed_authors><pubmed_authors>Chen-Wichmann L</pubmed_authors><pubmed_authors>Goebel B</pubmed_authors><pubmed_authors>Kaufmann KB</pubmed_authors></additional><is_claimable>false</is_claimable><name>CD133-targeted gene transfer into long-term repopulating hematopoietic stem cells.</name><description>Gene therapy for hematological disorders relies on the genetic modification of CD34(+) cells, a heterogeneous cell population containing about 0.01% long-term repopulating cells. Here, we show that the lentiviral vector CD133-LV, which uses a surface marker on human primitive hematopoietic stem cells (HSCs) as entry receptor, transfers genes preferentially into cells with high engraftment capability. Transduction of unstimulated CD34(+) cells with CD133-LV resulted in gene marking of cells with competitive proliferative advantage in vitro and in immunodeficient mice. The CD133-LV-transduced population contained significantly more cells with repopulating capacity than cells transduced with vesicular stomatitis virus (VSV)-LV, a lentiviral vector pseudotyped with the vesicular stomatitis vir</description><dates><release>2015-01-01T00:00:00Z</release><publication>2015 Jan</publication><modification>2026-04-29T07:43:39.155Z</modification><creation>2019-03-27T01:51:21Z</creation></dates><accession>S-EPMC4426797</accession><cross_references><pubmed>25189742</pubmed><doi>10.1038/mt.2014.173</doi></cross_references></HashMap>